oxidopamine has been researched along with MPTP Neurotoxicity Syndrome in 48 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal models have been invaluable to Parkinson's disease (PD) research." | 2.46 | Neurotoxic in vivo models of Parkinson's disease recent advances. ( Cannon, JR; Greenamyre, JT, 2010) |
| "Of these, neuroinflammation is one candidate that appears to accumulate more support with each passing year." | 2.46 | Modeling neuroinflammatory pathogenesis of Parkinson's disease. ( Barnum, CJ; Tansey, MG, 2010) |
| "The etiology of Parkinson's disease is not known." | 2.41 | Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. ( Grünblatt, E; Mandel, S; Youdim, MB, 2000) |
| "Apomorphine is a potent radical scavenger and iron chelator." | 2.40 | Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. ( Gassen, M; Grünblatt, E; Mandel, S; Youdim, MB, 1999) |
| " In both rodents and nonhuman primates, we observed successful engraftment and higher dopamine levels in hpNSC-transplanted animals compared to vehicle control animals, without any adverse events." | 1.42 | Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease. ( Abramihina, T; Crain, A; Elsworth, JD; Garitaonandia, I; Gonzalez, R; Jiang, C; Laurent, LC; Morey, R; Noskov, A; Poustovoitov, M; Redmond, DE; Semechkin, R; Snyder, EY, 2015) |
| " These results suggest creation of potential pro-toxic environment in the brain due to the long-term administration of L-DOPA, which may get further sensitized by the treatment of monoamine oxidase inhibitors." | 1.36 | L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. ( Borah, A; Mohanakumar, KP, 2010) |
| "Levodopa-unresponsive parkinsonism is present in 80% of MSA cases, and this dominant clinical presentation (MSA-P) is associated with a combined degeneration of the substantia nigra pars compacta and the striatum in anatomically related areas." | 1.33 | In vivo models of multiple system atrophy. ( Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F, 2005) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (20.83) | 18.2507 |
| 2000's | 17 (35.42) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 3 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Gaceb, A | 1 |
| Barbariga, M | 1 |
| Paul, G | 1 |
| Kozioł, E | 1 |
| Skalicka-Woźniak, K | 1 |
| Michalak, A | 1 |
| Kaszubska, K | 1 |
| Budzyńska, B | 1 |
| Liu, L | 1 |
| Chen, Y | 1 |
| Zeng, RF | 1 |
| Liu, Y | 1 |
| Xie, SS | 1 |
| Lan, JS | 1 |
| Ding, Y | 1 |
| Yang, YT | 1 |
| Yang, J | 1 |
| Zhang, T | 1 |
| Baufreton, J | 1 |
| Milekovic, T | 1 |
| Li, Q | 3 |
| McGuire, S | 1 |
| Moraud, EM | 1 |
| Porras, G | 2 |
| Sun, S | 1 |
| Ko, WKD | 1 |
| Chazalon, M | 1 |
| Morin, S | 1 |
| Normand, E | 1 |
| Farjot, G | 1 |
| Milet, A | 1 |
| Pype, J | 1 |
| Pioli, E | 2 |
| Courtine, G | 1 |
| Bessière, B | 1 |
| Bezard, E | 3 |
| Salari, S | 1 |
| Bagheri, M | 1 |
| Dardou, D | 1 |
| Monlezun, S | 1 |
| Foerch, P | 1 |
| Courade, JP | 1 |
| Cuvelier, L | 1 |
| De Ryck, M | 1 |
| Schiffmann, SN | 1 |
| Dagda, RK | 1 |
| Das Banerjee, T | 1 |
| Janda, E | 1 |
| Kermer, P | 1 |
| Köhn, A | 1 |
| Schnieder, M | 1 |
| Lingor, P | 1 |
| Bähr, M | 2 |
| Liman, J | 1 |
| Dohm, CP | 1 |
| Segura-Aguilar, J | 1 |
| Kostrzewa, RM | 1 |
| Gonzalez, R | 1 |
| Garitaonandia, I | 1 |
| Crain, A | 1 |
| Poustovoitov, M | 1 |
| Abramihina, T | 1 |
| Noskov, A | 1 |
| Jiang, C | 1 |
| Morey, R | 1 |
| Laurent, LC | 1 |
| Elsworth, JD | 1 |
| Snyder, EY | 1 |
| Redmond, DE | 1 |
| Semechkin, R | 1 |
| Fidalgo, C | 1 |
| Ko, WK | 1 |
| Tronci, E | 1 |
| Stancampiano, R | 1 |
| Chuan, Q | 1 |
| Carta, M | 1 |
| Garcia, E | 1 |
| Limon, D | 1 |
| Perez-De La Cruz, V | 1 |
| Giordano, M | 1 |
| Diaz-Muñoz, M | 1 |
| Maldonado, PD | 1 |
| Herrera-Mundo, MN | 1 |
| Pedraza-Chaverri, J | 1 |
| Santamaria, A | 2 |
| Di Benedetto, M | 1 |
| Cavina, C | 1 |
| D'Addario, C | 1 |
| Leoni, G | 1 |
| Candeletti, S | 1 |
| Cox, BM | 1 |
| Romualdi, P | 1 |
| Nagel, F | 1 |
| Dietz, GP | 1 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Kim, HG | 1 |
| Ju, MS | 1 |
| Shim, JS | 1 |
| Kim, MC | 1 |
| Lee, SH | 1 |
| Huh, Y | 1 |
| Kim, SY | 1 |
| Oh, MS | 1 |
| Tobón-Velasco, JC | 1 |
| Carmona-Aparicio, L | 1 |
| Ali, SF | 1 |
| Cannon, JR | 1 |
| Greenamyre, JT | 2 |
| Barnum, CJ | 1 |
| Tansey, MG | 1 |
| Jackson-Lewis, V | 2 |
| Blesa, J | 1 |
| Przedborski, S | 1 |
| Tieu, K | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Bordet, R | 1 |
| Fleming, SM | 1 |
| Schallert, T | 1 |
| Ciucci, MR | 1 |
| Morin, N | 1 |
| Jourdain, VA | 1 |
| Di Paolo, T | 1 |
| Aubin, N | 1 |
| Barneoud, P | 1 |
| Carter, C | 1 |
| Caille, D | 1 |
| Sontag, N | 1 |
| Marc, C | 1 |
| Lolivier, J | 1 |
| Gardes, A | 1 |
| Perron, C | 1 |
| Le Kim, A | 1 |
| Charieras, T | 1 |
| Pandini, M | 1 |
| Burnier, P | 1 |
| Puech, F | 1 |
| Jegham, S | 1 |
| George, P | 1 |
| Scatton, B | 1 |
| Curet, O | 1 |
| Fernagut, PO | 1 |
| Ghorayeb, I | 1 |
| Diguet, E | 1 |
| Tison, F | 1 |
| de Meira Santos Lima, M | 1 |
| Braga Reksidler, A | 1 |
| Marques Zanata, S | 1 |
| Bueno Machado, H | 1 |
| Tufik, S | 2 |
| Vital, MA | 2 |
| Malagelada, C | 1 |
| Ryu, EJ | 1 |
| Biswas, SC | 1 |
| Greene, LA | 1 |
| Uthayathas, S | 1 |
| Karuppagounder, SS | 1 |
| Tamer, SI | 1 |
| Parameshwaran, K | 1 |
| Degim, T | 1 |
| Suppiramaniam, V | 1 |
| Dhanasekaran, M | 1 |
| Lane, E | 1 |
| Dunnett, S | 1 |
| Gold, SJ | 1 |
| Hoang, CV | 1 |
| Potts, BW | 1 |
| Kim, KW | 1 |
| Nadjar, A | 1 |
| Qin, C | 1 |
| LaHoste, GJ | 1 |
| Bioulac, BH | 1 |
| Waugh, JL | 1 |
| Gurevich, E | 1 |
| Neve, RL | 1 |
| Da Cunha, C | 1 |
| Wietzikoski, EC | 1 |
| Ferro, MM | 1 |
| Martinez, GR | 1 |
| Hipólide, D | 1 |
| Canteras, NS | 1 |
| Tian, YM | 1 |
| Chen, X | 1 |
| Luo, DZ | 1 |
| Zhang, XH | 1 |
| Xue, H | 1 |
| Zheng, LF | 1 |
| Yang, N | 1 |
| Wang, XM | 1 |
| Zhu, JX | 1 |
| Bankiewicz, KS | 1 |
| Sanchez-Pernaute, R | 1 |
| Oiwa, Y | 1 |
| Kohutnicka, M | 1 |
| Cummins, A | 1 |
| Eberling, J | 1 |
| Bing, G | 1 |
| Zhang, Y | 1 |
| Watanabe, Y | 1 |
| McEwen, BS | 1 |
| Stone, EA | 1 |
| Richard, MG | 1 |
| Bennett, JP | 1 |
| Schwartz, JP | 1 |
| Sheng, JG | 1 |
| Mitsuo, K | 1 |
| Shirabe, S | 1 |
| Nishiyama, N | 1 |
| Roeling, TA | 1 |
| Docter, GJ | 1 |
| Voorn, P | 1 |
| Melchers, BP | 1 |
| Wolters, EC | 1 |
| Groenewegen, HJ | 1 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Bedard, PJ | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 1 |
| Robertson, GS | 1 |
| Offen, D | 1 |
| Beart, PM | 1 |
| Cheung, NS | 1 |
| Pascoe, CJ | 1 |
| Hochman, A | 1 |
| Gorodin, S | 1 |
| Melamed, E | 1 |
| Bernard, R | 1 |
| Bernard, O | 1 |
| Grünblatt, E | 2 |
| Mandel, S | 2 |
| Gassen, M | 1 |
| Youdim, MB | 2 |
| Bas, J | 1 |
| Calopa, M | 1 |
| Mestre, M | 1 |
| Molleví, DG | 1 |
| Cutillas, B | 1 |
| Ambrosio, S | 1 |
| Buendia, E | 1 |
| Blum, D | 1 |
| Torch, S | 1 |
| Lambeng, N | 1 |
| Nissou, M | 1 |
| Benabid, AL | 1 |
| Sadoul, R | 1 |
| Verna, JM | 1 |
| Lee, JI | 1 |
| Shin, HJ | 2 |
| Nam, DH | 1 |
| Kim, JS | 1 |
| Hong, SC | 1 |
| Park, K | 1 |
| Eoh, W | 1 |
| Kim, JH | 1 |
| Lee, WY | 1 |
| Luthman, J | 1 |
| Sundström, E | 1 |
| Kaakkola, S | 1 |
| Teräväinen, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of a Probiotic K10 in Managing Health Outcomes in Parkinson's Disease and in Early Stage (Mild Cognitive Impairment to Mild Dementia) Alzheimer's Disease[NCT06019117] | 104 participants (Anticipated) | Interventional | 2023-08-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for oxidopamine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
In vivo, in vitro and pharmacologic models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Humans; MPTP Poisoning; Oxidopamine; Parkinson Disease | 2019 |
How Parkinsonian toxins dysregulate the autophagy machinery.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Humans; Methamphetamine; Mitophagy; MPTP Po | 2013 |
Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models.
Topics: Animals; Biomarkers; Cell Death; Central Nervous System; Free Radicals; Humans; MPTP Poisoning; Oxid | 2010 |
Neurotoxic in vivo models of Parkinson's disease recent advances.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; MPTP Poisoning; Neurotoxicity Syndromes; Neurotox | 2010 |
Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dopamine; Humans; Inflammation; Lipopolysaccha | 2010 |
Animal models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Humans; Insecticides; Methamphetamine; MPTP Poisoning; Oxidopamine; | 2012 |
A guide to neurotoxic animal models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Haplorhini; Lewy Bodies; Mice; MPTP Poisoning; Neu | 2011 |
Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Disease Models, Animal; Feeding Behavior; Mice; M | 2012 |
Modeling dyskinesia in animal models of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; MPTP Poisoning; Oxi | 2014 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Dr | 2008 |
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; | 1993 |
Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.
Topics: Animals; Antioxidants; Apomorphine; Free Radical Scavengers; Iron Chelating Agents; Mice; MPTP Poiso | 1999 |
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
Topics: Animals; Disease Models, Animal; Humans; MPTP Poisoning; Neuroprotective Agents; Oxidopamine; Parkin | 2000 |
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.
Topics: Animals; Apoptosis; Dopamine; Humans; MPTP Poisoning; Nerve Degeneration; Oxidopamine; Sympatholytic | 2001 |
Animal models of parkinsonism.
Topics: Aging; Animals; Behavior, Animal; Disease Models, Animal; Hydroxydopamines; MPTP Poisoning; Oxidopam | 1990 |
33 other studies available for oxidopamine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
An In Vitro Partial Lesion Model of Differentiated Human Mesencephalic Neurons: Effect of Pericyte Secretome on Phenotypic Markers.
Topics: 1-Methyl-4-phenylpyridinium; Becaplermin; Cell Line; Cell Survival; Cells, Cultured; Culture Media, | 2020 |
Xanthotoxin reverses Parkinson's disease-like symptoms in zebrafish larvae and mice models: a comparative study.
Topics: Animals; Antiparkinson Agents; Biological Assay; Drug Discovery; Fruit; Larva; Male; Methoxsalen; Mi | 2021 |
Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
Topics: Animals; Coumarins; Drug Design; Indans; Mice; Models, Molecular; Molecular Structure; Monoamine Oxi | 2021 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Rel | 2018 |
A role for Sv2c in basal ganglia functions.
Topics: Animals; Basal Ganglia; Cocaine; Corpus Striatum; Dopaminergic Neurons; Enkephalins; Gene Knockdown | 2013 |
BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; Cell Line, Tumor; DNA-Binding Proteins; Humans; Mice; Mice, Inb | 2015 |
Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
Topics: Animals; Brain; Dopaminergic Neurons; Encephalitis; Humans; Mitochondria; MPTP Poisoning; Neurons; O | 2015 |
Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease.
Topics: Animals; Brain; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Disease Models, Animal; | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, | 2015 |
Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Basal Ganglia; Behavior, Animal | 2008 |
Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Blotting, Western; Caudate Nucleus; Gene Expression; Glutamate | 2009 |
Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
Topics: Amacrine Cells; Animals; Astrocytes; Cell Death; Cell Survival; Chromatography, High Pressure Liquid | 2009 |
L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Electrochemistry; Levodopa; Male; Mi | 2010 |
Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson's disease models.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Line; Disease Models, Animal; Dopamine; Dose-Response | 2010 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Anim | 2004 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice | 2005 |
Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase | 2006 |
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Camptothecin; DNA-Binding Proteins; Gene E | 2006 |
Evaluation of neuroprotective and anti-fatigue effects of sildenafil.
Topics: Animals; Fatigue; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Oxidopamin | 2007 |
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Dihydroxyphenylalanine; Disease Mo | 2007 |
Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Damage, Chronic; Disease Models, Animal; Dopamine; | 2008 |
Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Topics: Animals; Biomarkers; Blotting, Western; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane T | 2008 |
Preclinical models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injec | 2001 |
Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra.
Topics: Animals; Base Sequence; Dopamine; Immunohistochemistry; In Situ Hybridization; Locus Coeruleus; Mice | 1994 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Trophic factor production by reactive astrocytes in injured brain.
Topics: Aging; Animals; Astrocytes; Biomarkers; Cells, Cultured; Cerebellum; Enkephalin, Methionine; Enkepha | 1993 |
Effects of unilateral 6-hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis.
Topics: Animals; Basal Ganglia; Behavior, Animal; Callithrix; Dopamine; Dopamine Agents; Enkephalin, Methion | 1995 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.
Topics: Animals; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Drug Resistance; Glutathione; Heterozygo | 1998 |
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.
Topics: Aged; Animals; CD4-Positive T-Lymphocytes; Disease Models, Animal; Humans; Leukocyte Common Antigens | 2001 |
Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine.
Topics: Animals; Apomorphine; Dopamine Agonists; Male; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; | 2001 |
No apparent difference in the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the sympathetic system in NMRI and C57 BL/6 mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Heart; Hydroxydopamines; Injections, Subcutaneous; Iris; Male; | 1990 |